Iron overload and stem cell transplant-and the beat goes on

American Journal of Hematology

Volumn 86, Issue 10, 2011, Pages 825-826

  Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE;

AGRANULOCYTOSIS; ALLOGENEIC STEM CELL TRANSPLANTATION; EDITORIAL; EYE TOXICITY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEARING IMPAIRMENT; HUMAN; IRON CHELATION; IRON OVERLOAD; KIDNEY FAILURE; LIVER BIOPSY; LIVER FAILURE; MORTALITY; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; RISK ASSESSMENT;

CHELATION THERAPY; FEMALE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MYELODYSPLASTIC SYNDROMES; STEM CELL TRANSPLANTATION;

EID: 80052888070     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22138     Document Type: Editorial

References (26)

1. Tefferi A, Mesa RA, Pardanani A, et al. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol 2009; 84: 265-267.
2. Chee CE, Steensma DP, Wu W, et al. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol 2008; 83: 611-613.
3. Patnaik MM, Lasho TL, Finke CM, et al. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: Survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia 2010; 24: 1283-1289.
4. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 2005; 23: 7594-7603.
5. Tefferi A, Stone RM. Iron chelation therapy in myelodysplastic syndrome-Cui bono? Leukemia 2009; 23: 1373.
6. Tefferi A. Myelodysplastic syndromes-Many new drugs, little therapeutic progress. Mayo Clin Proc 2010; 85: 1042-1045.
7. Steensma DP. Myelodysplasia paranoia: Iron as the new radon. Leuk Res 2009; 33: 1158-1163.
8. DeLoughery TG. Iron: The fifth horseman of the apocalypse? Am J Hematol 2009; 84: 263-264.
9. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586-4588.
10. Pullarkat V, Blanchard S, Tegtmeier B, et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008; 42: 799-805.
11. Kataoka K, Nannya Y, Hangaishi A, et al. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 195-204.
12. Mahindra A, Bolwell B, Sobecks R, et al. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol 2009; 146: 310-316.
13. Tachibana T, Tanaka M, Takasaki H, et al. Pretransplant serum ferritin is associated with bloodstream infections within 100 days of allogeneic stem cell transplantation for myeloid malignancies. Int J Hematol 2011; 93: 368-374.
14. Maradei SC, Maiolino A, de Azevedo AM, et al. Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 2009; 114: 1270-1275.
15. Platzbecker U, Bornhauser M, Germing U, et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant 2008; 14: 1217-1225.
16. Mahindra A, Bolwell B, Sobecks R, et al. Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma. Biol Blood Marrow Transplant 2008; 14: 1239-1244.
17. de la Serna J, Bornstein R, Garcia-Bueno MJ, et al. Iron depletion by phlebotomy with recombinant erythropoietin prior to allogeneic transplantation to prevent liver toxicity. Bone Marrow Transplant 1999; 23: 95-97.
18. Tomas JF, Pinilla I, Garcia-Buey ML, et al. Long-term liver dysfunction after allogeneic bone marrow transplantation: Clinical features and course in 61 patients. Bone Marrow Transplant 2000; 26: 649-655.
19. Kamble RT, Selby GB, Mims M, et al. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 506-510.
20. Busca A, Falda M, Manzini P, et al. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: Quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy. Biol Blood Marrow Transplant 2010; 16: 115-122.
21. Majhail NS, Lazarus HM, Burns LJ. A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant 2010; 16: 832-837.
22. Lee JW, Kang HJ, Kim EK, et al. Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children. Bone Marrow Transplant 2009; 44: 793-797.
23. Durairaj S, Chew S, Hyslop A, et al. Predicted costs of iron-chelators in myelodysplastic syndromes: A 10-year analysis based on actual prevalence and red cell transfusion rates. Am J Hematol 2011; 86: 406-410.
24. Vichinsky E. Clinical application of deferasirox: Practical patient management. Am J Hematol 2008; 83: 398-402.
25. Taher A, Sheikh-Taha M, Koussa S, et al. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. Eur J Haematol 2001; 67: 30-34.
26. Cermak J, Jonasova A, Vondrakova J, et al. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. Hemoglobin 2011; 35: 217-227.